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A B S T R A C T
Mitochondria fragmentation destabilizes mitochondrial membranes, promotes oxidative stress and facilitates cell
death, thereby contributing to the development and the progression of several mitochondria-related diseases.
Accordingly, compounds that reverse mitochondrial fragmentation could have therapeutic potential in treating
such diseases. BGP-15, a hydroxylamine derivative, prevents insulin resistance in humans and protects against
several oxidative stress-related diseases in animal models. Here we show that BGP-15 promotes mitochondrial
fusion by activating optic atrophy 1 (OPA1), a GTPase dynamin protein that assist fusion of the inner mi-
tochondrial membranes. Suppression of Mfn1, Mfn2 or OPA1 prevents BGP-15-induced mitochondrial fusion.
BGP-15 activates Akt, S6K, mTOR, ERK1/2 and AS160, and reduces JNK phosphorylation which can contribute
to its protective effects. Furthermore, BGP-15 protects lung structure, activates mitochondrial fusion, and sta-
bilizes cristae membranes in vivo determined by electron microscopy in a model of pulmonary arterial hy-
pertension. These data provide the first evidence that a drug promoting mitochondrial fusion in in vitro and in
vivo systems can reduce or prevent the progression of mitochondria-related disorders.
1. Introduction
Mitochondria are the major energy-producing organelles, and play a
significant role in determining cell survival and death [1–4]. They are
dynamic organelles undergoing frequent fission and fusion cycles that
result in major morphological changes. Membrane bound dynamin
GTPases, dynamin-related protein 1 (Drp1), mitochondrial fission pro-
tein 1 (Fis1), mitofusin 1/2 (Mfn1/2) and optic atrophy 1 (OPA1) drive
these changes [5–7]. Mitochondrial fragmentation plays an important
role in the development and progression of several diseases, including
diabetes [4,8–12], neurodegenerative diseases [5,13,14], muscular
dystrophies [15,16], nonalcoholic fatty liver disease and other types of
hepatotoxicity [17–19], and pulmonary arterial hypertension (PAH)
[20,21] and several other diseases related to oxidative stress [2,22].
Reactive oxygen species (ROS) deriving from different sources
induce activated mitochondrial fission catalyzed by Drp1 and Fis1, and
lead to fragmented mitochondria [1–4,8]. These mitochondria have
lower membrane potential, produce less ATP, generate significantly
more ROS, and facilitate the release of proapoptotic mitochondrial
proteins [7,16,23]. Therefore, modulation of mitochondrial fission or
fusion pathways by synthetic chemicals could provide novel molecular
mechanism to protect cells in oxidative stress, and could be a new way
to design novel mitochondrial drugs.
BGP-15 (O-[3-piperidino-2-hydroxy-1-propyl]-nicotinic amidoxime)
possesses a wide range of cytoprotective effects [24–33] but lacks a
clear intracellular molecular target. BGP-15 protects the mitochondrial
membrane system, decreases oxidative stress [27,28], inhibits the nu-
clear translocation of apoptosis-inducing factor (AIF) from mitochon-
dria [27], and inhibits mitogen-activated protein kinase (MAPK) acti-
vation [26,29]. BGP-15 is effective in ameliorating obesity induced
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T
insulin resistance [29,33], improves insulin action in humans [30],
slows the progression of severe muscular dystrophy [24], and also in-
creases mitochondrial biogenesis [33] in rodents.
Based on the observations above, we raise the possibility that BGP-
15 can influence mitochondrial fragmentation, and provide evidence in
cultured cells that BGP-15-activated mitochondrial fusion requires ac-
tive OPA1, Mfn1/2 and Akt (also called protein kinase B). In addition,
we show that BGP-15 activates OPA1 GTPase and promotes its poly-
merization in vitro. Since oxidative stress and mitochondrial fragmen-
tation play important role in the development of PAH [20,21], we used
this model to provide evidence for the BGP-15-induced mitochondrial
fusion in an in vivo system.
2. Materials and methods
2.1. Materials
All chemicals for cell culture studies were from PAA Laboratories
(Cölbe, Germany) and Gibco/Invitrogen (Life Technologies, Carlsbad,
CA, USA). Hydrogen peroxide (H2O2), protease inhibitor mixture and
all remaining chemicals were purchased from Sigma–Aldrich Co.
(Budapest, Hungary). Fluorescent dye MitoTracker Red was obtained
from Molecular Probes (Life Technologies, Carlsbad, CA, USA).
Hematoxylin and eosin were purchased from Sigma–Aldrich Co. BGP-
15 was a gift from N-Gene (New York, NY, USA). The following primer
antibodies were used: anti-Akt, anti-phospho-Akt, anti-phospho-Akt
substrate of 160 kDa (AS160), anti-phospho-mammalian target of ra-
pamycin (mTOR), anti-phospho-p70 S6 kinase (S6K), anti-phospho-
p44/42 MAPK (ERK1/2), anti-phospho-p38 MAPK (p38), anti-phospho-
JNK MAPK (JNK1/2) (Cell Signaling Technology, Danvers, MA, USA),
anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (EMD
Millipore, Billerica, MA, USA), anti-Mfn1, anti-Mfn2, anti-Drp1, anti-
Fis1 (Santa Cruz Biotechnology, Heidelberg, Germany) and anti-OPA1
(Invitrogen; Life Technologies, Carlsbad, CA, USA). The horseradish
peroxidase-conjugated anti-mouse IgG and anti-rabbit IgG were ob-
tained from Sigma–Aldrich Co., XF Calibrant, XF Base Medium and XFp
Cell Mito Stress Test Kit including oligomycin, FCCP, rotenone/anti-
mycin A were purchased from Agilent Technologies (Kromat Ltd.,
Budapest, Hungary). All reagents were of the highest purity commer-
cially available.
2.2. Animals
Wistar male rats were purchased from Innovo Ltd. (Gödöllő,
Hungary). The investigation conformed to the Guide for the Care and
Use of Laboratory Animals published by the US National Institutes of
Health, and was approved by the Animal Research Review Committee
of the University of Pécs, Hungary. All animals were housed one or two
per cage, under optimal laboratory conditions (controlled temperature,
humidity and 12:12 h light-dark cycles) with free access to water and
standard rodent chow. Starting at 8 weeks of age, the animals were
assigned into four groups. Eight animals were allocated to control group
receiving subcutaneous injection of isotonic saline (0.1 ml/kg) on day
0. Eight animals were allocated to BGP-15 group receiving sub-
cutaneous injection of isotonic saline (0.1 ml/kg) on day 0 and BGP-15
(20mg/kg per day, per os, in the drinking water) from day 0 to day 28.
Eight animals were allocated to PAH group receiving 60mg/kg sub-
cutaneous injection of monocrotaline (MCT) on day 0. Eight animals
were allocated to PAH+BGP-15 group receiving 60mg/kg sub-
cutaneous injection of MCT on day 0 and BGP-15 (20mg/kg per day,
per os, in the drinking water) from day 0 to day 28.
2.3. Cell cultures
WRL-68 (HeLa derivative), C2C12 (mouse C3H muscle myoblast),
A549 (human lung carcinoma) and Sf9 (derived from pupal ovarian
tissue of Spodoptera frugiperda) cell lines were obtained from the
European Collection of Cell Cultures (Salisbury, UK). The WRL-68,
C2C12 and A549 cell lines were maintained in a humidified 5% CO2
atmosphere at 37 °C while Sf9 cells were cultured in a 100% air at-
mosphere at 27 °C. WRL-68 cells were cultured in Eagle's minimum
essential medium (MEM), C2C12 and A549 cells in Dubelcco modified
Eagle's medium (DMEM) (PAA Laboratories) while Sf9 cells in TC-100
insect medium (Sigma–Aldrich Co.). All media contained 10% bovine
serum and antibiotic solution (1% penicillin and streptomycin mixture)
(Gibco/Invitrogen). Cells were passaged at 3-day intervals.
Cells were seeded at a starting density of 5×105 cells/well in a 6-
well plate for immunoblotting and at a density of 1×105 cells/well for
fluorescent or confocal laser scanning microscopy.
2.4. Immunoblot analysis
The WRL-68 cells were seeded into a 6-well plate and cultured
overnight. After subjecting the cells to 50 μM BGP-15 for 3 h, the cells
were harvested in ice-cold lysis buffer containing 0.5mM sodium me-
tavanadate, 1 mM ethylenediaminetetraacetic acid (EDTA), and pro-
tease inhibitor mixture in phosphate-buffered saline (PBS). The proteins
were precipitated by trichloroacetic acid, washed three times with
−20 °C acetone, and subjected to sodium-dodecyl sulphate poly-
acrylamide gel electrophoresis. Proteins (20 µg/lane) were separated on
12% gels and then transferred to nitrocellulose membranes. The
membranes were blocked in 5% low-fat milk for 1 h at room tempera-
ture and then exposed to primary antibodies at 4 °C overnight at the
manufacturer’s proposed dilution in blocking solution. Appropriate
horseradish peroxidase-conjugated secondary antibodies were used for
2 h at room temperature in 1:5000 dilution. Peroxidase labeling was
visualized with enhanced chemiluminescence using the SuperSignal
West Pico chemiluminescent substrate (Life Technologies).
2.5. Construction of mitochondria-directed red and green fluorescent
proteins
Mitochondria-directed enhanced red fluorescent protein (mERFP)
expressing plasmid was constructed as follows: The mitochondrial tar-
geting sequence (MTS) was amplified by polymerase chain reaction
(PCR) from cytochrome c oxidase subunit VIIIa (COX8A) gene (RZPD),
and the amplified sequence was inserted into pDsRed-Monomer-N1
mammalian expression plasmid (Clontech, Takara Bio Europe, Saint-
Germain-en-Laye, France) between XhoI and HindIII restriction sites.
Construction of plasmid for the expression of mitochondria-directed
enhanced green fluorescent protein (mEGFP) are described below: MTS
was amplified from cytochrome c oxidase subunit VIIIa coding se-
quence (from RZPD) by PCR and ligated into pEGFP-N3 mammalian
expression plasmid (Clontech) between BglII and SalI restriction sites.
2.6. Polyethylene glycol (PEG) fusion assay
The PEG fusion assay was performed as described previously [34].
Briefly, WRL-68 cells were transiently transfected with mERFP or
mEGFP fluorescent protein. The next day, the PEG fusion assays were
then performed. WRL-68 cells expressing mERFP were co-plated with
WRL-68 cells expressing mEGFP on glass coverslips. Cycloheximide
(20 μg/ml) was added 30min before fusion. The 70–100% confluent
cells in a 35-mm culture dish were then washed with MEM without
serum and incubated for exactly 1min with 750 μl of a prewarmed
(37 °C) solution of PEG 1500 (50% [wt/vol] in MEM, Sigma–Aldrich
Co.). The cultures were fixed in 4% formalin, and the cells were vi-
sualized by Nikon Eclipse Ti-U fluorescent microscope equipped with a
Spot RT3 camera using a 60× objective and epifluorescent illumina-
tion.
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2.7. Suppression of Akt, Mfn1, Mfn2 or OPA1 expression by siRNA
WRL-68 cells were transiently transfected with siRNA designed by
the manufacturer (Santa Cruz Biotechnology) to silence Akt, Mfn1,
Mfn2 or OPA1 in Opti-MEM I reduced serum medium using
Lipofectamine 2000. Silencing efficiency was tested by immunoblot,
using a polyclonal anti-Akt, anti-Mfn1, anti-Mfn2 or anti-OPA1 primary
antibody.
2.8. Determination of mitochondrial fragmentation
WRL-68, C2C12 and A549 cells were seeded on glass coverslips and
cultured at least overnight before the experiment. The cells were either
transiently transfected with mERFP or treated and labeled using
MitoTracker Red (50 nM) dye. Next day after transfection, cells were
washed twice in PBS, and then treated as indicated in the text. After two
washings, cells were fixed in 4% formalin and visualized by Olympus
FluoView 1000 confocal laser scanning microscope. Excitation by
multiline argon-ion laser at 488 nm and green helium-neon laser at
543 nm was used, respectively, for 10 µs/pixel in photon counting and
sequential mode. The field of interest was scanned in XYZ mode,
scanning the total thickness of the cells with 1.5 µm layer distance
taking 1024× 1024 pixel/layer images. 3D reconstruction of samples
was achieved by the Imaris 4.2.0 software (Bitplane, Concord, MA,
USA). Quantitative determination of mitochondrial fragmentation was
performed as described before [35], and we considered as fragmented
mitochondria those shorter than 2 μm and as filamental mitochondria
those longer than 5 μm. MitoTracker Red labeled cells were visualized
by Nikon Eclipse Ti-U fluorescent microscope equipped with a Spot RT3
camera using a 60× objective and epifluorescent illumination. The
mitochondrial images were binarized by the ‘threshold’ module in Im-
ageJ, and these binary images were converted to images 1 pixel wide by
the ‘skeletonize’ module. Finally, mitochondrial length was determined
using the ‘analyze particles’ module. Analyses were performed by an
investigator blind to the experiment on at least 25 randomly chosen
cells.
2.9. OPA1 GTPase assay and OPA1-OPA1 interactions
Mutant human OPA1 construct was made by GeneCust
(Luxembourg, Germany). Chemically synthetized polynucleotide/DNA
corresponding to human OPA1 (Genbank NM_015560.2) amino acid
residues 210–960 and 8 His was inserted into pFastBac 1 plasmid vector
(Invitrogen Life Technologies) between SalI and NotI restriction sites.
His-tagged OPA 1 mutant protein was expressed in Sf9 cells and pur-
ified from cell pellets using Ni-NTA agarose beads (Sigma–Aldrich Co.)
according to the corresponding manual. OPA1 GTPase reactions were
performed with 0–0.150 μg/ml OPA1 in 50mM hydroxyethyl piper-
azine ethanesulfonic acid (HEPES; pH 7.0), 1 mM dithiothreitol at
300mM NaCl concentrations, and the GTP hydrolysis was quantified by
monitoring the released free phosphate using a malachite green assay at
37 °C for 90min.
Amino functionalized magnetic micro particles from Sigma–Aldrich
Co. were activated by glutaraldehyde as described in the manual.
Recombinant OPA1 was immobilized to magnetic beads; 2 μg OPA1 to
60 μg magnetic particles. The reaction took place for 180min and was
blocked with 100mM ethanolamide for 60min. Magnetic beads were
washed three times with reaction buffer; 5 mM HEPES containing
150mM NaCl, 2 mM MgCl2 at pH 8.0. OPA1-OPA1 interactions were
determined in 0.5ml reaction buffer containing 60 μg OPA1 im-
mobilized magnetic particles and 6 μg recombinant OPA1, shaken for
60min at 25 °C, separated and non-covalently bound OPA1 was re-
moved from the beads by 1M ammonium hydroxide and its quantity
was determined by enzyme-linked immunosorbent assay (ELISA).
2.10. Determination of oxygen consumption
Oxygen consumption rate (OCR) was determined by Agilent
Seahorse XFp Analyzer (Kromat Ltd.). A549 cells were seeded in XFp
Miniplate at the density of 1.5× 104 cells/well in 80 µl complete
growth medium (DMEM containing 10% FBS) and incubated at 37 °C,
5% CO2 for 24 h. On the day prior to assay, XFp Sensor Cartridge was
hydrated in XF Calibrant at 37 °C in a non-CO2 incubator overnight. On
the day of the assay, cells were treated for 3 h with 0 (control) or
10 μmol/107 cells H2O2 in the absence or presence of BGP-15 (50 µM).
After the treatment, complete growth medium was removed and re-
placed with assay medium consisting of Agilent XF Base Medium sup-
plemented with 10mM glucose, 1 mM pyruvate and 2mM glutamine,
pH 7.4. The plate was placed into a 37 °C non-CO2 incubator for 1 h.
Before the measurement, oligomycin, carbonyl cyanide 4-(tri-
fluoromethoxy)phenylhydrazone (FCCP) and rotenon/antimycin A
were loaded in the injection ports of the sensor cartridge. Final con-
centration of the aforementioned compounds was 1 µM and three
measurements were taken after each injection.
2.11. Lung histology
Lungs were removed on day 28 after euthanasia by isoflurane in-
halation, quickly blotted free of blood, weighed, and processed as re-
quired for histology. Lungs from 4 rats of each group were fixed in 6%
formalin, embedded in paraffin, and sectioned 5 µm thin by a micro-
tome. The sections were stained with hematoxylin–eosin, and digital
photos were taken. Average wall thickness of alveolar sac was de-
termined at randomly chosen 25 different sites in each section.
Macrophages were counted in 10 non-overlapping high power fields
(200×) in each section by an expert who was blind to the experiment.
2.12. Electron microscopy
For electron microscopy analysis, 1–2mm3 blocks were cut from
lung samples and fixed using modified Kranovsky fixative (2% paraf-
ormaldehyde, 2.5% glutaraldehyde, 0.1 M Na-cacodylate buffer, pH 7.4
and 3mM CaCl2). After samples were washed in phosphate buffer, they
were incubated in 1% osmium tetroxide in 0.1M PBS for 35min.
Samples were then washed in buffer several times for 10min and de-
hydrated in an ascending ethanol series, including a step of uranyl
acetate (1%) solution in 70% ethanol to increase contrast. Dehydrated
blocks were transferred to propylene oxide before being placed in
Durcupan resin (Sigma–Aldrich Co.) and then embedded in gelatin
capsules containing Durcupan. The blocks were placed in an incubator
for 48 h at 56 °C. From the embedded blocks, 1 µm thick semithin and
serial ultrathin sections (70 nm) were prepared with a Leica ultra-
microtome and mounted on mesh or on collodion-coated (Parlodion,
Electron Microscopy Sciences, Fort Washington, PA, USA), single-slot,
copper grids. Additional contrast was provided with uranyl acetate and
lead citrate solutions; sections were then examined using a
JEOL1200EX-II electron microscope.
2.13. Statistics
All data were expressed as means ± standard error of mean (SEM)
from replicate determinations. ANOVA with a post hoc correction was
used to determine differences. The Student’s t test was used to compare
the mean values of two groups. Differences were regarded as significant
when the p value was< .05.
A. Szabo et al. Biochemical Pharmacology 150 (2018) 86–96
88
3. Results
3.1. BGP-15 attenuated oxidative stress-induced mitochondrial
fragmentation
Based on our previous studies [24–33], we assumed that BGP-15
affects mitochondrial fusion/fission. Dose-dependently [36], H2O2 in-
duces various cellular damages; at the dose of 10 μmol/107 cells it
caused mitochondrial fission resulting in fragmented mitochondria
within 4–6 h that was detected by either MitoTracker Red staining, or
by mERFP transfection (Fig. 1). H2O2-induced mitochondrial fragmen-
tation was significantly reduced by 10–50 μM BGP-15 in mERFP-labeled
WRL-68 cells (Fig. 1A–C). In C2C12 mouse muscle myoblasts, treatment
with 10 μmol/107 cells H2O2 for 5 h induced mitochondrial fragmen-
tation, which was also prevented by treatment with BGP-15 (Fig. 1D
and E).
Fig. 1. BGP-15 protects against oxidative
stress-induced mitochondrial fragmentation in
WRL-68 cells and C2C12 muscle myoblasts.
(A) BGP-15 (50 μM) protects against oxidative
stress-induced (10 μmol/107 cells H2O2) mi-
tochondrial fragmentation in WRL-68 cells;
fragmented mitochondria were shorter than
2 μm and filamental mitochondria were longer
than 5 μm. Mitochondria were labeled by mi-
tochondria directed-ERFP. (B) Quantitative
analysis of H2O2-induced mitochondrial frag-
mentation and its reduction by BGP-15
(50 µM) in WRL-68 cells. (C) Quantitative
analysis of H2O2-induced mitochondrial frag-
mentation and its reduction by BGP-15
(10 µM) in WRL-68 cells. (D) BGP-15 (50 µM)
protects against oxidative stress-induced
(50 μM H2O2) mitochondrial fragmentation in
C2C12 muscle myoblast cells. Mitochondria
were visualized by 50 nM MitoTracker Red. (E)
Quantitative analysis of the protective effect of
BGP-15 against oxidative stress-induced mi-
tochondrial fragmentation in C2C12 muscle
myoblast cells. (F) BGP-15 (50 μM) increases
the expression of mitochondrial fusion proteins
- Mfn1, Mfn2 and OPA1- determined by im-
munoblot in WRL-68 cells. (G) Quantitative
analysis of effect of BGP-15 on Mfn1, Mfn2 and
OPA1. (H) BGP-15 (50 μM) increases the ex-
pression of mitochondrial fission protein Drp1
and decreases the expression of Fis1 de-
termined by immunoblot in WRL-68 cells. (I)
Quantitative analysis of effect of BGP-15 on
Drp1 and Fis1. Data are presented as
mean ± SEM of three independent experi-
ments. In (B, C and E) *** p≤ .001 compared
to control cells; ### p≤ .001 compared to
H2O2 treated cells. In (G and I) * p≤ .05 **
p≤ .01 compared to control group (Student’s
t-test)
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Fig. 2. BGP-15 activates mitochondrial fusion in WRL-68 cells. (A) Mitochondrial fragmentation was induced by H2O2 (10 μmol/107 cells) for 4 h, and fragmented mitochondria were
kept in fresh original media, or in fresh media containing 50 μM BGP-15 for another 4 h. Mitochondria were visualized by 50 nM MitoTracker Red. (B) Quantitative analysis of BGP-15
activated mitochondrial fusion of fragmented mitochondria. (C) BGP-15 facilitates mitochondrial fusion after PEG-mediated cell fusion of mEGFP and mERFP labeled WRL-68 cells. (D)
Quantitative analysis of BGP-15 activated mitochondrial fusion after PEG-mediated cell fusion. Data are presented as mean ± SEM of three independent experiments. ** p≤ .01 and ***
p≤ .001 compared to control cells; ## p≤ .01 compared to H2O2 treated cells (Student’s t-test).
Fig. 3. Suppression of Mfn1 -a critical component of outer mitochondrial fusion machinery- prevents BGP-15 induced mitochondrial fusion in WRL-68 cells. (A) Suppression of Mfn1
induces mitochondrial fragmentation and attenuates BGP-15-promoted mitochondrial fusion. Mitochondria were visualized by 50 nM MitoTracker Red. (B) Quantitative analysis of
mitochondrial fragmentation induced by Mfn1 suppression. (C) Immunoblot showing the suppression of Mfn1 by siRNA. (D) Mfn1 suppression abolishes BGP-15-induced (50 μM)
mitochondrial fusion in oxidative stress (10 μmol/107 cells H2O2, 5 h). (E) Quantitative analysis of BGP-15-induced mitochondrial fusion in Mfn1-suppresed cells in oxidative stress. Data
are presented as mean ± SEM of three independent experiments. In (B), *** p≤ .001 compared to control cells; in (E), *** p≤ .001 compared to Mfn1-suppressed cells (Student’s t-test).
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In addition, we analyzed the effect of BGP-15 on the expression of
mitochondrial fusion related genes. These data show that BGP-15
treatment causes small but significant increases in the expression of
mitochondrial fusion proteins Mfn1, Mfn2 and OPA1 determined by
immunoblot analysis (Fig. 1F and G). Analysis of mitochondrial fission
proteins Drp1 and Fis1 give contradictory data, namely increased Drp1
expression but decreased Fis1 expression after BGP-15 treatment
(Fig. 1H and I). Therefore, it was difficult to draw any conclusion from
these results, although it seemed more likely that BGP-15 increased
mitochondrial fusion rather than reducing fission.
3.2. BGP-15 promoted fusion
Next, we treated WRL-68 cells with 10 μmol/107 cells H2O2 for 4 h,
Fig. 4. Suppression of Mfn2-a critical component of outer mitochondrial fusion machinery- prevents BGP-15 induced mitochondrial fusion in WRL-68 cells. (A) Suppression of Mfn2
induces mitochondrial fragmentation and attenuates BGP-15-promoted mitochondrial fusion. Mitochondria were visualized by 50 nM MitoTracker Red. (B) Quantitative analysis of
mitochondrial fragmentation induced by Mfn2 suppression. (C) Immunoblot showing the suppression of Mfn2 by siRNA. (D) Mfn2 suppression abolishes BGP-15-induced (50 μM)
mitochondrial fusion in oxidative stress (10 μmol/107 cells H2O2, 5 h). (E) Quantitative analysis of BGP-15-induced mitochondrial fusion in Mfn2-suppresed cells in oxidative stress. Data
are presented as mean ± SEM of three independent experiments. In (B), *** p≤ .001 compared to control cells; in (E), *** p≤ .001 compared to Mfn2-suppressed cells (Student’s t-test).
Fig. 5. Suppression of OPA1 -a critical component of inner mitochondrial fusion machinery- prevents BGP-15 induced mitochondrial fusion in WRL-68 cells. (A) Suppression of OPA1
induces mitochondrial fragmentation and prevents BGP-15 promoted mitochondrial fusion. Mitochondria were visualized by 50 nM MitoTracker Red. (B) Quantitative analysis of
mitochondrial fragmentation in OPA1-suppresed cells. (C) Immunoblot showing the suppression of OPA1 by siRNA. (D) BGP-15 (50 μM) cannot prevent oxidative stress-induced
(10 μmol/107 cells H2O2, 5 h) mitochondrial fragmentation in OPA1-suppresed cells. (E) Quantitative analysis of BGP-15-induced mitochondrial fusion in OPA1-suppresed cells in
oxidative stress. Data are presented as mean ± SEM of three independent experiments. In (B), *** p≤ .001 compared to control cells; in (E), *** p≤ .001 compared to OPA1-suppressed
cells (Student’s t-test).
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and, as expected, mitochondrial fragmentation was detected by
MitoTracker Red labeling (Fig. 2A and B). After the H2O2 treatment, the
medium was replaced to a fresh one containing or not 50 μM BGP-15 to
determine the reformation of mitochondrial filaments. Cells cultured in
control medium for 4 h were unable to reform mitochondrial filaments
(Fig. 2A and B) while cells cultured in medium containing 50 μM BGP-
15 for 4 h were able to recover and reform mitochondrial filaments
likely by activation of fusion.
3.3. Measuring mitochondrial fusion by mitochondrial matrix targeted
green and red fluorescent proteins
To confirm this observation with an independent method, WRL-68
cells were transfected with mERFP, or mEGFP, were mixed, and fused
using PEG. After the removal of PEG, the cells were cultured and treated
with 50 μM BGP-15 for 5 h and fixed. Mitochondrial fusion was de-
tected by fluorescent microscopy (Fig. 2C). The rate of migration of red
and green fluorescence proteins to the other cells showed that mi-
tochondrial fusion occurred in control cells (Fig. 2C and D), but BGP-15
displayed a much faster rate of mitochondrial fusion, as determined by
Fig. 6. Critical role of Akt in BGP-15-activated mitochondrial fusion in WRL-68 cells. (A) Effect of BGP-15 (50 μM) on Akt-AS160 and Akt-mTOR pathways. (B) Quantitative analysis of
effect of BGP-15 on Akt-AS160 and Akt-mTOR pathways. (C) Effect of BGP-15 on mitochondrial fragmentation, and oxidative stress-induced (10 μmol/107 cells H2O2, 5 h) fragmentation
in Akt suppressed cells. Mitochondria were visualized by 50 nM MitoTracker Red. (D) Quantitative analysis of effect of BGP-15 on mitochondrial fragmentation in Akt suppressed cells. (E)
Immunoblot showing the suppression of Akt by siRNA. (F) Effect of BGP-15 (50 μM) on MAPK phosphorylation (JNK, ERK and p38). (G) Quantitative analysis of effect of BGP-15 on JNK,
ERK and p38 MAPK. We failed to detect JNK2 phosphorylation under our experimental conditions. Data are presented as mean ± SEM of three independent experiments. In (B and G),*
p≤ .05, ** p≤ .01 and *** p≤ .001 compared to control group; in (D), *** p≤ .001 compared to control cells (Student’s t-test).
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the faster migration rate of red or green fluorescent protein into the
mitochondria of the neighboring cells (Fig. 2C and D). These experi-
ments show that BGP-15 promoted mitochondrial fusion in living cells.
3.4. BGP-15-induced mitochondrial fusion required active outer membrane
and inner membrane fusion machinery
Mfn1 and Mfn2-essential proteins of mitochondrial outer membrane
fusion-were suppressed by siRNA that induced some level of mi-
tochondrial fragmentation in unstressed cells (Figs. 3A and B and 4A
and B), which could not been reversed by BGP-15 (Figs. 3A and B and
4A and B). Oxidative stress induced further mitochondrial fragmenta-
tion in Mfn1 and Mfn2 silenced cells, and again, BGP-15 could not
rescue mitochondria from ROS-induced fragmentation (Figs. 3D and E
and 4D and E) indicating that outer membrane fusion machinery is
required for the protective effect of BGP-15 (Figs. 3A, B, D and E and
4A, B, D and E).
OPA1 plays an essential role in fusion of the inner mitochondrial
membrane; its suppression by siRNA induced more mitochondrial
fragmentation as compared to normal cells (Fig. 5A and B). BGP-15
(50 μM) could not reverse this partial fragmentation (Fig. 5A and B).
Oxidative stress further increased mitochondrial fragmentation, and
BGP-15 was again ineffective to prevent it (Fig. 5D and E).
3.5. Akt activation was required for mitochondrial fusion
BGP-15 activated Akt and induced the phosphorylation of some
related kinases, mTOR, S6K and AS160 (Fig. 6A and B); a process that
can play important role in the protection of mitochondrial membrane
systems [37,38]. Therefore, we analyzed the effect of Akt suppression
on BGP-15 induced fusion. Fig. 6C and D show that silencing of Akt
induced mitochondrial fragmentation. Oxidative stress-induced mi-
tochondrial fragmentation was significantly reduced by BGP-15 in
normal cells (Fig. 1A–C); however, BGP-15 could not prevent or reduce
ROS-induced mitochondrial fragmentation in Akt suppressed cells
(Fig. 6C and D). These data show that active Akt is required for
mitochondrial fusion, and the BGP-15-mediated prevention of mi-
tochondrial fragmentation requires Akt. We studied the effect of BGP-
15 on the MAPKs; BGP-15 significantly activated ERK1/2 phosphor-
ylation and reduced JNK1 phosphorylation (Fig. 6F and G), which could
be advantageous for mitochondrial function. Phosphorylation of p38
was too low to detect under our experimental conditions (Fig. 6F and
G).
3.6. BGP-15 facilitated GTPase activity and self-aggregation of OPA1
The protective effect of BGP-15 in cristae membrane damages sug-
gests a role of OPA1 in BGP-15-mediated mitochondrial protection.
OPA1 GTPase assay showed that recombinant short OPA1 hydrolyzed
GTP in a concentration dependent manner (Fig. 7A), as expected. BGP-
15 facilitated GTP hydrolysis by OPA1 (Fig. 7B), which process may
have contributed to the bioenergetics basis of mitochondrial cristae
protection. This observation suggests also that OPA1 can be the first
direct molecular target of BGP-15. Since BGP-15 activates GTP hydro-
lysis by OPA1 (Fig. 7B), it can provide more energy to hold together
mitochondrial cristae membranes and activates mitochondrial fusion.
Also, we analyzed the effect of BGP-15 on the OPA1-OPA1 inter-
action (Fig. 7C), by crosslinking OPA1 protein to amino groups con-
taining magnetic beads and studying the interaction between im-
mobilized OPA1 and free OPA1 in the solution. Fig. 7C shows that BGP-
15 increased aggregation of OPA1 on the magnetic beads, providing
direct evidence that BGP-15 increased the interactions between OPA1
molecules.
3.7. Evidence for the BGP-15-induced mitochondrial fusion in vivo in
pulmonary arterial hypertension model
A549 lung epithelial cells demonstrated many long mitochondrial
filaments under normal conditions, while oxidative stress induced mi-
tochondrial fragmentation and the disappearance of the mitochondrial
filaments (Fig. 8A and B). Adding BGP-15 to the media prevented the
intensive mitochondrial fragmentation induced by oxidative stress, and
Fig. 7. BGP-15 facilitates GTPase activity and self-aggregation of OPA1. (A) GTP-ase activity of recombinant OPA1 (amounts in μg/ml are depicted on x axis) was assessed by measuring
the released inorganic phosphate (y axis) by malachite green assay. (B) Effect of BGP-15 on the GTPase activity of recombinant OPA1. Released phosphate (y axis) resulting from
spontaneous hydrolysis of GTP (only GTP 1mM), hydrolysis assisted by 150 μg/ml recombinant OPA1 (OPA1) and 150 μg/ml recombinant OPA1+50 μM BGP-15 (OPA1+BGP-15). (C)
BGP-15 promotes OPA1-OPA1 interactions. Aggregate formation (y axis) in the absence (OPA1) and presence (OPA1+BGP-15) of BGP-15. Data are presented as mean ± SEM of three
independent experiments. In (B), *** p≤ .001 compared to enzyme free group, # p≤ .05 compared to OPA1 group; in (C), *** p≤ .001 compared to OPA1 group (Student’s t-test).
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kept mitochondria predominantly in the filamentous state (Fig. 8A and
B). The effect of BGP-15 (50 μM) and H2O2 (10 μmol/107) on the OCR
was determined by Seahorse XFp Analyzer (Fig. 8C). BGP-15 did not
modify the rate of mitochondrial respiration. H2O2 induced a slight
decrease, while BGP-15 induced a small, but not significant increase in
OCR together with H2O2 compared to only H2O2. All of these data show
that under our experimental conditions H2O2-induced inactivation of
respiratory complexes does not play significant role in the BGP-15-
mediated mitochondrial fusion processes.
In MCT-induced PAH, ROS initiates lung epithelial cell damage
which contributes to disease development. Therefore, we analyzed the
role of mitochondrial fragmentation in MCT-induced rat PAH model.
Histopathological study of lung tissue in control and BGP-15 treated
groups showed the alveolar sac and bronchioles with normal epithelium
(Fig. 8D and E), while in MCT treated group small pulmonary vessels
with inflammatory lesions and extensive vascular remodeling with in-
timal and medial hypertrophy of the muscular arteries as well as in-
terstitial fibrosis could be detected. In addition, mean thickness of
Fig. 8. BGP-15 activates mitochondrial fusion in vivo in
PAH. (A) BGP-15 (50 μM) protects against oxidative
stress-induced (10 μmol/107 cells H2O2, 5 h) mi-
tochondrial fragmentation in A549 lung epithelial
cells. Mitochondria were visualized by 50 nM
MitoTracker Red. (B) Quantitative analysis of the
protective effect of BGP-15 against oxidative stress-
induced mitochondrial fragmentation. (C) Effect of
BGP-15 and H2O2 on the oxygen consumption rate
(OCR) in A549 cells measured by Seahorse FXp
Analyzer. (D) Effect of BGP-15 on MTC-induced lung
damages in PAH model. Formalin fixed lungs sections
were stained by hematoxylin eosin, and subjected to
histopathological analysis. Representative stained sec-
tions are presented. (E) Quantitative analysis of mean
wall thickness of alveolar sac in PAH model (n=4 rats
for each group). (F) Effect of BGP-15 on mitochondrial
structure of lung type II pneumocytes in MCT-induced
PAH model by electron microscopy. (G) Quantitative
analysis of effect of BGP-15 on mitochondrial structure
in MCT-induced PAH model. (H) Schematic model for
BGP-15 induced mitochondrial fusion and Akt activa-
tion leading to prevention of cell death. Red and green
colors denote the action of ROS and BGP-15, respec-
tively. Pointed arrows represent activation while flat
ones inhibition. Data are presented as mean ± SEM of
three independent experiments. In (B), *** p≤ .001
compared to control cells, ### p≤ .001 compared to
H2O2 treated cells; in (E), *** p≤ .001 compared to
control group, ### p≤ .001 compared to PAH group;
in (G) * p≤ .05, ** p≤ .01 compared to control group,
# p≤ .05 compared to PAH group (Student’s t-test).
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alveolar sacs was highly increased (Fig. 8D and E). BGP-15 treated PAH
animal lungs showed improved histological appearance, diminished
infiltration with inflammatory cells, decreases in the thickness of al-
veolar sacs (Fig. 8D and E) indicating that BGP-15 imposed a major
protective effect in PAH.
Transmission electron microscopic analysis showed severe damages
in alveolar structure in lung of PAH rats compared to control and BGP-
15 treated animals. The mitochondria of type II pneumocytes in control
rats differed from the mitochondria of PAH rats. The structure of the
mitochondrial cristae was normal, dense matrix was seen and the shape
of mitochondria showed normal heterogeneity (ellipsoid, oval-shaped,
rounded rod-like) in the control group as shown by arrows (Fig. 8F and
G). Mitochondria of type II pneumocytes in PAH rats were often
rounded and swollen, the mitochondrial matrix was very light and
cristae structure was unclear. The mitochondrial ultrastructure in the
PAH+BGP-15 group was similar to that of the healthy rats. The
structure of the mitochondrial cristae was almost normal, dense matrix
was seen and the mitochondria were less swollen (Fig. 8F and G). These
data demonstrate that BGP-15 could prevent mitochondrial cristae
membrane damages, and reduced mitochondrial fragmentation in an in
vivo PAH model.
4. Discussion
It is well documented that ROS initiate mitochondrial fragmentation
and contribute to the development and progression of various diseases
[2,7,8]. Therefore, it would be very useful to find a way to reverse
mitochondrial fragmentation. Here, we provide evidence that BGP-15
prevented oxidative stress-induced mitochondrial fragmentation in
several cell lines and in an in vivo PAH model. These data suggest that
BGP-15 might protect against ROS-induced damage in vivo, and to the
best of our knowledge, it is the first small synthetic molecule that
promotes mitochondrial fusion (Fig. 2).
We demonstrated that the prevention of ROS-induced mitochondrial
fragmentation by BGP-15 required the existence of active outer and
inner membrane fusion machinery; suppression of Mfn1, Mfn2 or OPA1
eliminated the effect of the drug (Figs. 3–5). These observations are
supported by our previous data in different model systems showing that
BGP-15 suppressed ROS production/oxidative damage, AIF release and
caspase activation, and protected the respiratory chain from damage
[26–28,39]. Furthermore, active mitochondrial fusion is important not
only to maintain mitochondrial integrity and to reduce mitochondrial
ROS production, but also to activate mitochondrial DNA (mtDNA) re-
plication elevating mtDNA copy number [40].
Since BGP-15 reduce mitochondrial ROS production [39], we as-
sumed that this effect can be related to OPA1 and its GTPase activity,
because it was shown that the short isoform of OPA1 is responsible for
maintaining of mitochondrial cristae structure and the oxidative
phosphorylation function [41]. Here, we verified that BGP-15 activated
GTP hydrolysis of recombinant OPA1 (Fig. 7). Therefore, BGP-15 acted
in a unique fashion to trigger GTP hydrolysis of OPA1 that may re-
present the molecular mechanism underlying the fusion of inner mi-
tochondrial membranes. Consequently, it is very likely that activation
of mitochondrial fusion by synthetic small molecules affecting OPA1
function can be an effective way for the prevention of mitochondrial
fragmentation.
Another way to prevent mitochondrial fragmentation is to inhibit or
suppress Drp1, an essential mitochondrial fission protein. Inhibition of
fission has positive effect on the short run [42,43], but on the long run
it may cause problems with autophagy, development, and cell cycle
regulation according to knockout mice data [44]. In addition, a recent
publication suggests that the major cytoprotective effect of mitochon-
drial division inhibitor (mdivi-1) – a widely used Drp-1 inhibitor – is not
induced via direct inhibition of Drp-1 but via the reversible inhibition
of complex I resulting in reduced ROS production [45]. However, we
found that BGP-15 does not modify mitochondrial oxidation at
physiologically relevant concentrations (Fig. 8), suggesting that BGP-15
has a different molecular mechanism.
It is well established that significantly increased oxidative stress and
mitochondrial fragmentation caused by the mutations in the dystrophin
gene play role in the development of severe muscular dystrophy [16].
Therefore, the prevention of mitochondrial fragmentation by the acti-
vation of fusion could be advantageous in this disease. Previously, it
was found that BGP-15 slowed the progression of severe muscular
dystrophy in an animal model, and this effect was considered to be
mediated via increasing heat shock protein (HSP) 72 expression [24].
However, it is more likely that BGP-15-induced activation of mi-
tochondrial fusion and Akt can play a significant role in the reduced
progression of muscular dystrophy. Moreover, BGP-15-induced Akt
activation via inactivation of glycogen synthase kinase 3β (GSK-3β) can
facilitate heat shock response preventing GSK-3β-induced inactivation
of heat shock factor 1 [46] that may explain the role of HSP 72.
Whereas, oxidative stress and mitochondrial fragmentation also
play significant role in the development of PAH [20,21], we in-
vestigated the potential mitochondrial fusion-inducing effect of BGP-15
on this in vivo model. We found that BGP-15 effectively maintained the
structure of mitochondrial cristae and reduced MCT-induced mi-
tochondrial fragmentation (Fig. 8).
In conclusion, the activation of mitochondrial fusion and the related
Akt induction (Fig. 8H) can be protective mechanisms in a wide variety
of diseases in which mitochondrial fission is important such as diabetes,
muscular dystrophies, neurodegenerative diseases, and PAH. The in-
duction of mitochondrial fusion by OPA1 GTPase activation may im-
prove the survival and quality of life of patients with a number of
common disorders.
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